kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
807
JPY
-14
(-1.71%)
Mar 13, 3:30 pm JST
5.06
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
7.41
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
809 JPY 5.08 USD
Previous Close Mar 12
821 JPY 5.16 USD
High Mar 13, 9:00 am
809 JPY 5.08 USD
Low Mar 13, 9:15 am
790 JPY 4.96 USD
Volume
82,500
Trading Value
0.07B JPY 0.41M USD
VWAP
799.94 JPY 5.02 USD
Minimum Trading Value
80,700 JPY 506 USD
Market Cap
9.38B JPY 0.06B USD
Number of Trades
236
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
563
1-Year High Mar 26, 2025
14,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 296,000
Feb 27, 2026 0 343,700
Feb 20, 2026 0 336,800
Feb 13, 2026 0 314,800
Feb 6, 2026 0 313,100
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.